These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

162 related items for PubMed ID: 25155387

  • 1. Structure-based design of a novel series of azetidine inhibitors of the hepatitis C virus NS3/4A serine protease.
    Parsy C, Alexandre FR, Brandt G, Caillet C, Cappelle S, Chaves D, Convard T, Derock M, Gloux D, Griffon Y, Lallos L, Leroy F, Liuzzi M, Loi AG, Moulat L, Musiu C, Rahali H, Roques V, Seifer M, Standring D, Surleraux D.
    Bioorg Med Chem Lett; 2014 Sep 15; 24(18):4444-4449. PubMed ID: 25155387
    [Abstract] [Full Text] [Related]

  • 2. Synthesis and antiviral evaluation of a novel series of homoserine-based inhibitors of the hepatitis C virus NS3/4A serine protease.
    Alexandre FR, Brandt G, Caillet C, Chaves D, Convard T, Derock M, Gloux D, Griffon Y, Lallos L, Leroy F, Liuzzi M, Loi AG, Moulat L, Musiu C, Parsy C, Rahali H, Roques V, Seifer M, Standring D, Surleraux D.
    Bioorg Med Chem Lett; 2015 Sep 15; 25(18):3984-91. PubMed ID: 26231161
    [Abstract] [Full Text] [Related]

  • 3. Discovery and structural diversity of the hepatitis C virus NS3/4A serine protease inhibitor series leading to clinical candidate IDX320.
    Parsy CC, Alexandre FR, Bidau V, Bonnaterre F, Brandt G, Caillet C, Cappelle S, Chaves D, Convard T, Derock M, Gloux D, Griffon Y, Lallos LB, Leroy F, Liuzzi M, Loi AG, Moulat L, Chiara M, Rahali H, Roques V, Rosinovsky E, Savin S, Seifer M, Standring D, Surleraux D.
    Bioorg Med Chem Lett; 2015 Nov 15; 25(22):5427-36. PubMed ID: 26410074
    [Abstract] [Full Text] [Related]

  • 4. Molecular modeling based approach to potent P2-P4 macrocyclic inhibitors of hepatitis C NS3/4A protease.
    Liverton NJ, Holloway MK, McCauley JA, Rudd MT, Butcher JW, Carroll SS, DiMuzio J, Fandozzi C, Gilbert KF, Mao SS, McIntyre CJ, Nguyen KT, Romano JJ, Stahlhut M, Wan BL, Olsen DB, Vacca JP.
    J Am Chem Soc; 2008 Apr 09; 130(14):4607-9. PubMed ID: 18338894
    [Abstract] [Full Text] [Related]

  • 5. Discovery of novel, potent and bioavailable proline-urea based macrocyclic HCV NS3/4A protease inhibitors.
    Vendeville S, Nilsson M, de Kock H, Lin TI, Antonov D, Classon B, Ayesa S, Ivanov V, Johansson PO, Kahnberg P, Eneroth A, Wikstrom K, Vrang L, Edlund M, Lindström S, Van de Vreken W, McGowan D, Tahri A, Hu L, Lenz O, Delouvroy F, Van Dooren M, Kindermans N, Surleraux D, Wigerinck P, Rosenquist A, Samuelsson B, Simmen K, Raboisson P.
    Bioorg Med Chem Lett; 2008 Dec 01; 18(23):6189-93. PubMed ID: 18954982
    [Abstract] [Full Text] [Related]

  • 6. Potent inhibitors of the hepatitis C virus NS3 protease: use of a novel P2 cyclopentane-derived template.
    Johansson PO, Bäck M, Kvarnström I, Jansson K, Vrang L, Hamelink E, Hallberg A, Rosenquist A, Samuelsson B.
    Bioorg Med Chem; 2006 Aug 01; 14(15):5136-51. PubMed ID: 16675222
    [Abstract] [Full Text] [Related]

  • 7. Novel potent hepatitis C virus NS3 serine protease inhibitors derived from proline-based macrocycles.
    Chen KX, Njoroge FG, Arasappan A, Venkatraman S, Vibulbhan B, Yang W, Parekh TN, Pichardo J, Prongay A, Cheng KC, Butkiewicz N, Yao N, Madison V, Girijavallabhan V.
    J Med Chem; 2006 Feb 09; 49(3):995-1005. PubMed ID: 16451065
    [Abstract] [Full Text] [Related]

  • 8. Azetidines and spiro azetidines as novel P2 units in hepatitis C virus NS3 protease inhibitors.
    Bondada L, Rondla R, Pradere U, Liu P, Li C, Bobeck D, McBrayer T, Tharnish P, Courcambeck J, Halfon P, Whitaker T, Amblard F, Coats SJ, Schinazi RF.
    Bioorg Med Chem Lett; 2013 Dec 01; 23(23):6325-30. PubMed ID: 24135727
    [Abstract] [Full Text] [Related]

  • 9. The design of a potent inhibitor of the hepatitis C virus NS3 protease: BILN 2061--from the NMR tube to the clinic.
    Tsantrizos YS.
    Biopolymers; 2004 Dec 01; 76(4):309-23. PubMed ID: 15386268
    [Abstract] [Full Text] [Related]

  • 10. Novel 2-oxoimidazolidine-4-carboxylic acid derivatives as hepatitis C virus NS3-4A serine protease inhibitors: synthesis, activity, and X-ray crystal structure of an enzyme inhibitor complex.
    Arasappan A, Njoroge FG, Parekh TN, Yang X, Pichardo J, Butkiewicz N, Prongay A, Yao N, Girijavallabhan V.
    Bioorg Med Chem Lett; 2004 Dec 06; 14(23):5751-5. PubMed ID: 15501035
    [Abstract] [Full Text] [Related]

  • 11. Toward the Synthesis of Fluorinated Analogues of HCV NS3/4A Serine Protease Inhibitors Using Methyl α-Amino-β-fluoro-β-vinylcyclopropanecarboxylate as Key Intermediate.
    Milanole G, Andriessen F, Lemonnier G, Sebban M, Coadou G, Couve-Bonnaire S, Bonfanti JF, Jubault P, Pannecoucke X.
    Org Lett; 2015 Jun 19; 17(12):2968-71. PubMed ID: 26053226
    [Abstract] [Full Text] [Related]

  • 12. Molecular modeling based approach, synthesis and in vitro assay to new indole inhibitors of hepatitis C NS3/4A serine protease.
    Ismail NS, Hattori M.
    Bioorg Med Chem; 2011 Jan 01; 19(1):374-83. PubMed ID: 21138791
    [Abstract] [Full Text] [Related]

  • 13. P2-P4 macrocyclic inhibitors of hepatitis C virus NS3-4A serine protease.
    Arasappan A, Njoroge FG, Chen KX, Venkatraman S, Parekh TN, Gu H, Pichardo J, Butkiewicz N, Prongay A, Madison V, Girijavallabhan V.
    Bioorg Med Chem Lett; 2006 Aug 01; 16(15):3960-5. PubMed ID: 16730985
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Discovery of GS-9451: an acid inhibitor of the hepatitis C virus NS3/4A protease.
    Sheng XC, Appleby T, Butler T, Cai R, Chen X, Cho A, Clarke MO, Cottell J, Delaney WE, Doerffler E, Link J, Ji M, Pakdaman R, Pyun HJ, Wu Q, Xu J, Kim CU.
    Bioorg Med Chem Lett; 2012 Apr 01; 22(7):2629-34. PubMed ID: 22366653
    [Abstract] [Full Text] [Related]

  • 16. Hepatitis C virus NS3-4A serine protease inhibitors: SAR of P'2 moiety with improved potency.
    Arasappan A, Njoroge FG, Chan TY, Bennett F, Bogen SL, Chen K, Gu H, Hong L, Jao E, Liu YT, Lovey RG, Parekh T, Pike RE, Pinto P, Santhanam B, Venkatraman S, Vaccaro H, Wang H, Yang X, Zhu Z, Mckittrick B, Saksena AK, Girijavallabhan V, Pichardo J, Butkiewicz N, Ingram R, Malcolm B, Prongay A, Yao N, Marten B, Madison V, Kemp S, Levy O, Lim-Wilby M, Tamura S, Ganguly AK.
    Bioorg Med Chem Lett; 2005 Oct 01; 15(19):4180-4. PubMed ID: 16087332
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. A new method for induced fit docking (GENIUS) and its application to virtual screening of novel HCV NS3-4A protease inhibitors.
    Takaya D, Yamashita A, Kamijo K, Gomi J, Ito M, Maekawa S, Enomoto N, Sakamoto N, Watanabe Y, Arai R, Umeyama H, Honma T, Matsumoto T, Yokoyama S.
    Bioorg Med Chem; 2011 Nov 15; 19(22):6892-905. PubMed ID: 21992802
    [Abstract] [Full Text] [Related]

  • 19. Inhibitors of hepatitis C virus NS3.4A protease 2. Warhead SAR and optimization.
    Perni RB, Pitlik J, Britt SD, Court JJ, Courtney LF, Deininger DD, Farmer LJ, Gates CA, Harbeson SL, Levin RB, Lin C, Lin K, Moon YC, Luong YP, O'Malley ET, Rao BG, Thomson JA, Tung RD, Van Drie JH, Wei Y.
    Bioorg Med Chem Lett; 2004 Mar 22; 14(6):1441-6. PubMed ID: 15006379
    [Abstract] [Full Text] [Related]

  • 20. High-throughput cell-based screening for hepatitis C virus NS3/4A protease inhibitors.
    Lee JC, Yu MC, Lien TW, Chang CF, Hsu JT.
    Assay Drug Dev Technol; 2005 Aug 22; 3(4):385-92. PubMed ID: 16180993
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.